Fundamental Analysis of Vertex Pharmaceuticals Inc - Growth / Value Index


VRTX - Valuation Highlights

Valuation Analysis

   Undervalued - Price to Intrinsic Value of 0.064
   Tremendous increasing in Book Value last 3 year
   Price to Book Ratio of 6.62 suggesting that it is very expensive
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 28.79 33.07 -4.78 %
Price to Book 6.87 6.53 -21.29 % 6.27
Price to Sales 11.36 11.88 -8.00 %
Enterprise Value to EBITDA Multiple 24.66 28.42 20.11 %


VRTX - Profitability Highlights

Profitability Analysis

   Tsr Profitability Index - Good Score of 69.38
   Excellent Net Margin for last 3 years
   Excellent QoQ /QoQ FY EPS growth
   Company Earning excess return
   During the past twelve months, the company has given a strong Return On Equity of 21.69%
   During the past twelve months, the company has given a strong Net Margin of 39.46%
   All key Trailing Twelve Months Margin growing by 15 %
   Annual Net Profit in last 3 years is trending up
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Steady Growth in EPS for last four quarters
   Good Return On Capital Employed of 19.74
   Very Low Dividend Yield of 0 %
   Low Earning Yield of 3.61 %
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 21.69 19.74 -17.34 % 5.93
Return On Asset 18.66 15.26 -16.60 % 4.60
Net Profit Margin 39.46 35.94 -3.38 % 40.87
Operating Profit Margin 41.60 45.67 -5.30 % 45.20
EBITDA Margin 41.65 38.07 -23.34 % 42.35


Highlights
Market Cap114887 M
Enterprise Value104602 M
Price/Book TTM6.87
Outstanding Share258052 K
Float/ Outstanding Share99.73%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No2.89
Peter Lynch Ratio0.174
Piotroski F Score6.00
Altman Z Score15.50
Sloan Ratio-0.0401
Peter Lynch Fair Value386.56


VRTX - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Quarterly sales in last 5 years is trending up
   Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 10185.00 M 8.10 % 6.87 %
Gross Profit 8852.10 M 7.98 % 9.46 %
EBITDA 4242.40 M 17.13 % 9.74 %
Net Profit 4019.40 M 4.45 % 13.50 %
EPS 15.46 5.02 % NA


VRTX - Stability Highlights

Stability Analysis

   Tsr Stability Index - Excellent Score of 93.75
   Altman Z Score of 15.00 suggests good Stability
   Cash ratio of 3.16
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0048 -25.91 % 0.0045
Cash Ratio 3.16 -28.67 %
Quick Ratio 3.78 -24.84 % 3.29
Shareholders Equity 77.34 0.905 %
Debt to EBITDA 0.0228 12.98 %


Historical Valuation Ratios of Vertex Pharmaceuticals Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Vertex Pharmaceuticals Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Vertex Pharmaceuticals Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Vertex Pharmaceuticals Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)